APOE and Alzheimer disease: Consistent with previous studies showing associations between ApoE4 and more abnormal AD biomarkers, we found that ApoE4-carriers had overall stronger abnormal changes in CSF markers of Aβ1–42 and p-tau181 at baseline, supporting the role of ApoE4 as a major AD risk factor [45, 46].